Union Ministry of Health amended Drugs Rules, 1945 to bring cell/stem cell products, gene therapies, and xenografts under central licensing (CLAA framework).
UPSC angle — Polity headlines become exam-worthy when constitutional design meets institutional accountability.
Dekho, amendment Drugs Rules, 1945 mein hua hai — ye wo rules hain jo Drugs and Cosmetics Act, 1940 ke under banaye gaye the. Ab cell-based products, stem cell therapies, gene therapy products aur xenografts ko explicitly central licensing ke scope mein laa diya gaya hai, yani inki manufacturing aur sale ki license ab Central Licensing Approving Authority (CLAA) hi approve karegi.
Pehle in therapies ke liye ek regulatory ambiguity thi — kaha jaata tha ki ye 'drugs' ke under aate hain ya nahi, aur state-level drug controllers apne level pe licenses issue kar dete the ya clinics bina proper oversight ke chal rahe the. Ab amendment se ye clear ho gaya ki ye products squarely central net ke andar hain.
Iska sabse bada direct impact ye hai ki ab koi bhi clinic ya manufacturer stem cell ya gene therapy product market mein laane se pehle CLAA se rigorous evaluation pass karna padega — safety, efficacy aur quality ke standards meet karne padenge. Ye unproven cures ka check karna seekhta hai.
Socho, India mein last kuch saalon mein stem cell clinics mushroom kar gaye the — jo autism, cerebral palsy, diabetes jaisi conditions ke liye 'stem cell therapy' offer karte the bina kisi solid clinical evidence ke. Patients desperate hote hain, paise dete hain, aur ye treatments scientifically unproven hote hain — sometimes harmful bhi.
The gap was this: Drugs and Cosmetics Act traditionally 'drugs' ko regulate karta hai, but stem cells aur gene therapies ki nature alag hai — ye living cells ya genetic material hote hain, conventional chemical drugs nahi. Toh law mein explicit mention nahi tha, aur regulatory ambiguity ka faida uthaya ja raha tha.
Ab amendment se ye products explicitly defined aur centrally licensed honge, yani unproven cures offer karne wale clinics ko ab central authority ki sanction chahiye — wo bina evidence treatments nahi bech payenge. ICMR aur DBT ke guidelines the, but guidelines advisory hote hain; ab ye statutory backing ke saath enforceable hai.
Stem cell products mein stem cells use hote hain — ye body ke aise cells hote hain jo self-renew kar sakte hain aur different cell types mein convert ho sakte hain. Therapy ka idea hai ki damaged tissues ko regenerate kiya ja sake, lekin except for a few conditions like blood disorders, most applications are still experimental.
Gene therapy mein genetic material ko patient ke cells mein deliver kiya jaata hai — ya toh kisi faulty gene ko replace ya repair karne ke liye, ya naya gene add karne ke liye. Ye inherited disorders, certain cancers, aur viral infections ke liye promising hai but still largely in clinical trial stage globally.
Xenografts mein ek species ke tissues ya organs ko doosri species mein transplant kiya jaata hai — jaise pig ke organs ka humans mein use. Ye organ shortage problem solve karne ki direction mein ek frontier area hai but immunological rejection aur zoonotic infection risks bahut serious hain, isliye strict regulation zaroori hai.
India ka drug regulatory system two-tier hai. State Drug Controllers state-level licenses issue karte hain for conventional drugs, while CDSCO — jo is the apex regulator under the Centre — certain categories ke liye central licensing karta hai through CLAA.
CLAA specifically wo products regulate karta hain jinki complexity aur risk level high hai, jaise vaccines, sera, r-DNA products, aur ab stem cell/gene therapy products bhi. Central licensing ka logic simple hai — jab product complex, novel, aur high-risk ho, toh state-level drug controllers ke paas expertise aur infrastructure nahi hota usko properly evaluate karne ka.
Central body ke paas specialized committees, expert panels aur better technical capacity hoti hai. Ye DCGI (Drugs Controller General of India) ke office ke under aata hai, jo CDSCO ka head hai.
DCGI ki mandate hai ki India mein drugs aur cosmetics ki safety, efficacy aur quality ensure kare. Ab stem cell aur gene therapy products bhi is mandate ke scope mein formally a gaye hain.
Yeh bahut important hai samajhna — amendment regulatory gap close karta hai, lekin iska matlab ye nahi ki stem cell ya gene therapies ab sasti ya easily available ho jayengi. In fact, stricter licensing se initially availability decrease bhi ho sakti hai kyunki jo clinics bina evidence chal rahe the wo band ho jayenge.
Gene therapies globally bahut expensive hain — kuch treatments ki cost crore mein hoti hai. India mein affordability aur accessibility ka issue alag hai aur uska solution regulation se nahi, balki R&D investment, domestic manufacturing capacity, aur pricing policy se aayega.
Ye amendment sirf safety ka gatekeeper hai, access ka enabler nahi. Long-term mein, agar central licensing se standardized, evidence-based therapies develop hoti hain aur domestic manufacturing badhta hai, toh costs decrease ho sakti hain.
But ye ek gradual process hai — immediate effect sirf regulatory discipline ka hoga, affordability ka nahi.
This is a governance + S&T intersection: regulating emerging biotech therapies through drug law, closing a regulatory vacuum where unproven stem cell cures were proliferating, and the tension between stricter regulation vs affordability/access.
Practice MCQs
Consider the following statements regarding the recent amendment to the Drugs Rules, 1945: 1. It brings stem cell products and gene therapies under the purview of the Central Licensing Approving Authority. 2. It immediately makes stem cell and gene therapies cheaper and more accessible to patients. 3. It aims to address the proliferation of unproven stem cell-based cures. How many of the statements given above are correct?
- A. Only one
- B. Only two
- C. All three
- D. None
Statements 1 and 3 are correct — the amendment brings these therapies under CLAA and targets unproven cures. Statement 2 is the TRAP: the amendment does NOT make therapies cheaper or more accessible; it is a regulatory measure, not an access measure.
With reference to the Central Licensing Approving Authority (CLAA) in India, which of the following best describes its role?
- A. It is a state-level body that licenses conventional over-the-counter drugs
- B. It is a central authority under CDSCO that licenses high-risk and complex biological products
- C. It is an independent tribunal that adjudicates disputes on drug pricing
- D. It is a body under the Ministry of Science and Technology that funds stem cell research
CLAA operates under CDSCO and handles central licensing for high-risk, complex products like vaccines, sera, r-DNA products, and now stem cell and gene therapy products. The trap is confusing it with state drug controllers or thinking it is a pricing/tribunal body.
Consider the following pairs: 1. Stem cell therapy — Uses cells that can self-renew and differentiate into various cell types 2. Gene therapy — Involves delivering genetic material to repair or replace faulty genes 3. Xenograft — Transplantation of organs or tissues from one species to another Which of the pairs given above are correctly matched?
- A. Only one pair
- B. Only two pairs
- C. All three pairs
- D. None of the pairs
All three pairs are correctly matched. Stem cells self-renew and differentiate; gene therapy delivers genetic material to fix faulty genes; xenografts involve cross-species transplantation. The trap would be confusing xenograft with allograft (same species transplant).
The recent amendment to the Drugs Rules, 1945 bringing stem cell and gene therapies under central licensing is primarily aimed at:
- A. Reducing the cost of imported medical equipment
- B. Closing the regulatory gap that allowed unproven cures to proliferate
- C. Transferring drug licensing powers entirely to state governments
- D. Promoting private investment in pharmaceutical manufacturing
The amendment's primary purpose is to close the regulatory gap where clinics offered unproven stem cell cures without central oversight. The trap is option C — the amendment does the opposite, bringing these to central, not state, licensing.
This is a governance + S&T intersection: regulating emerging biotech therapies through drug law, closing a regulatory vacuum where unproven stem cell cures were proliferating, and the tension between stricter regulation vs affordability/access.
Model answer (150 words)
The amendment to Drugs Rules, 1945, bringing stem cell products, gene therapies, and xenografts under the Central Licensing Approving Authority (CLAA) is a significant step in India's healthcare governance. Earlier, regulatory ambiguity allowed clinics to offer unproven stem cell cures for conditions like autism and cerebral palsy without scientific evidence, exploiting patient desperation.
By mandating central licensing, the amendment ensures rigorous safety, efficacy, and quality evaluation before such therapies reach patients. However, the amendment is a regulatory measure, not an access measure.
Gene therapies are globally expensive, often costing crores. Stricter licensing may initially reduce availability as non-compliant clinics shut down.
Affordability requires separate interventions — domestic R&D investment, manufacturing capacity, and pricing mechanisms. The way forward lies in balancing regulation with access promotion: encouraging indigenous development of cell and gene therapies, supporting clinical trials through ICMR-DBT frameworks, and eventually exploring insurance coverage and price control for proven therapies.
India must ensure that safety regulation becomes a foundation for equitable access, not a barrier to it.
Fuller answer (250 words)
India's amendment to the Drugs Rules, 1945, bringing stem cell products, gene therapies, and xenografts under the Central Licensing Approving Authority (CLAA) marks a pivotal shift in regulating emerging biotech therapies. The Drugs and Cosmetics Act, 1940 traditionally regulated conventional chemical drugs, but stem cells, gene therapies, and xenografts involve living cells and genetic material — fundamentally different in nature and risk.
This regulatory gap was exploited by clinics offering unproven stem cell cures for conditions like autism, cerebral palsy, and diabetes, without clinical evidence, putting patients at risk. The amendment addresses this by mandating that all such products undergo central evaluation for safety, efficacy, and quality before market access.
CLAA, operating under CDSCO and the DCGI, has the technical expertise and specialized committees that state drug controllers lack, making central licensing appropriate for high-risk, novel therapies. This aligns India's framework with global regulatory practice where advanced therapies require centralized oversight.
However, significant challenges remain. First, the amendment does not make therapies cheaper or more accessible — gene therapies globally cost crores, and stricter licensing may initially reduce availability.
Second, India lacks sufficient domestic manufacturing capacity for cell and gene therapy products, meaning dependence on imports. Third, affordability requires separate policy interventions — R&D investment, public-funded clinical trials, pricing mechanisms, and insurance coverage.
Fourth, building CLAA's own technical capacity to evaluate complex biological products is itself a challenge requiring specialized expertise. The way forward requires a dual track: maintaining rigorous regulatory standards to protect patients from unproven cures, while simultaneously investing in indigenous R&D through ICMR-DBT frameworks, supporting domestic biotech manufacturing, and developing pricing and insurance models for proven therapies.
Only then can regulation become a foundation for equitable access rather than a barrier.
Prelims angle: Which products are now under CLAA — stem cell products, gene therapies, xenografts. Also the distinction: CLAA is central-level licensing under CDSCO, not state drug controllers.
Statement-based question likely.
Health Ministry ne Drugs Rules, 1945 mein amendment karke stem cell products, gene therapies aur xenografts ko ab Central Licensing Approving Authority (CLAA) ke under laa diya hai — matlab in treatments ki license ab sirf centre degi, state-level drug controllers nahi, aur ye mainly unproven cures ko rokne ka step hai.
This brief is generated by ClearUPSC Oracle's reasoning pipeline and mapped to the UPSC syllabus.
Not affiliated with UPSC. Always verify official details at upsc.gov.in.